Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Qiagen ( (QGEN) ) has issued an announcement.
Qiagen disclosed that the Dutch financial regulator AFM has published a substantial shareholding notification regarding positions held by Goldman Sachs Group in Qiagen. The filing shows Goldman Sachs holds a total interest of 3.06% in Qiagen’s share capital and voting rights through a mix of directly held ordinary shares, convertible bonds, warrants, swaps and options, reflecting both real and potential indirect stakes via various group entities.
The notification details that only a small portion of Goldman Sachs’s position is classified as real indirect share ownership, with the majority representing potential exposure through derivatives and other financial instruments. While Qiagen stresses it is not responsible for the accuracy of the AFM data, the disclosure underscores ongoing institutional investor activity in its stock and may signal continued trading and hedging strategies by a major global financial institution around Qiagen’s equity.
The most recent analyst rating on (QGEN) stock is a Hold with a $52.00 price target. To see the full list of analyst forecasts on Qiagen stock, see the QGEN Stock Forecast page.
More about Qiagen
Qiagen N.V. is a Netherlands-based life sciences company specializing in sample and assay technologies for molecular diagnostics, applied testing, academic research and pharmaceutical development. Its shares are listed in Frankfurt and traded on several other European exchanges as well as the NYSE and Swiss markets, giving it broad international investor exposure.
Average Trading Volume: 1,973,130
Technical Sentiment Signal: Strong Buy
Current Market Cap: $10.5B
See more data about QGEN stock on TipRanks’ Stock Analysis page.